9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose

9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose

Inhaled nitric oxide (iNO) is an uncharged, lipophilic gas that serves as an endogenous cell-signaling molecule and a revolutionary targeted pharmacotherapy in neonatal and pediatric critical care. In the transitioning newborn, failure of pulmonary vascular resistance (PVR) to fall normally after birth leads to Persistent Pulmonary Hypertension of the Newborn (PPHN). Elevated pulmonary arterial pressure exceeding systemic arterial pressure drives unoxygenated venous blood across fetal right-to-left shunts (the patent ductus arteriosus and patent foramen ovale), resulting in life-threatening hypoxemia refractory to conventional mechanical ventilation. Inhaled nitric oxide reverses this pathophysiological cycle by providing potent, selective pulmonary vasodilation.

---

Molecular Mechanism of Action & Selective Pulmonary Vasodilation

Understanding the cellular pathway of nitric oxide is fundamental to mastering its clinical pharmacology and avoiding systemic adverse events.

                    [Inhaled Nitric Oxide (iNO) in Alveolus]
                                       │
                                       │ Rapid Alveolar-Capillary Diffusion
                                       ▼
                    [Pulmonary Vascular Smooth Muscle Cell]
                                       │
                                       ▼
                      Activates Soluble Guanylyl Cyclase (sGC)
                                       │
                                       ▼
                             GTP ─────────► cGMP
                                            │
                                            ▼
                                Stimulates Protein Kinase G (PKG)
                                            │
                     ┌──────────────────────┴──────────────────────┐
                     ▼                                             ▼
           Dephosphorylates Myosin                    Sequester Intracellular Ca2+
                 Light Chains                         & Block Voltage-Gated Influx
                     │                                             │
                     └──────────────────────┬──────────────────────┘
                                            ▼
                             PULMONARY VASODILATION
                                       │
                                       │ Transits into Capillary Lumen
                                       ▼
                              [Erythrocyte in Blood]
                                       │
                     Binds Hemoglobin with Ultra-High Affinity
                     (Forms Nitrosyl-Hb ──► Rapidly Oxidized to MetHb)
                                       │
                                       ▼
                    PREDOMINANT PULMONARY EFFECT / MONITOR SYSTEMIC PRESSURE

1. Cellular Signal Transduction

1. Diffusion: Following inhalation, gaseous NO diffuses rapidly across the alveolar epithelial membrane, the interstitial space, and the capillary endothelial wall directly into adjacent vascular smooth muscle cells.
2. Enzyme Activation: NO binds with high affinity to the heme moiety of soluble guanylyl cyclase (sGC), inducing a conformational change that accelerates the catalytic conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP).
3. Calcium Extrusion & Muscle Relaxation: Elevated intracellular cGMP activates cGMP-dependent protein kinase G (PKG). PKG phosphorylates specific target proteins, resulting in:
   • Phosphorylation and activation of sarcoplasmic reticulum calcium-ATPase (SERCA), pumping free $\text{Ca}^{2+}$ into the sarcoplasmic reticulum.
   • Inhibition of voltage-dependent L-type calcium channels, halting extracellular calcium influx.
   • Dephosphorylation of myosin light chains via activation of myosin light chain phosphatase.
   • Result: Intracellular calcium concentrations plunge, producing rapid vascular smooth muscle relaxation and arteriolar dilation.
4. Metabolism: Cellular cGMP is subsequently degraded into inactive 5'-GMP by the enzyme phosphodiesterase type 5 (PDE-5). (This enzyme is the pharmacological target of sildenafil, which prevents cGMP breakdown and sustains vasodilation).

2. The Twin Hallmarks of Selectivity

What distinguishes iNO from systemic vasodilators (e.g., nitroprusside, hydralazine, prostacyclin infusions) is its double selectivity:

1. Ventilation-Perfusion (V/Q) Selectivity (Intrapulmonary Targeting):
   • Because iNO is delivered via the gas phase, it enters only well-ventilated lung units.
   • Pulmonary arterioles adjacent to well-ventilated alveoli dilate, redistributing pulmonary blood flow away from non-ventilated, atelectatic, or consolidated regions toward ventilated alveoli.
   • This microvascular redistribution dramatically improves $V/Q$ matching, decreases intrapulmonary right-to-left shunt, and improves arterial oxygenation without causing generalized hyperperfusion of collapsed lung segments.
2. Relative Pulmonary Circulation Selectivity:
   • As soon as iNO transits across the vascular wall into the capillary lumen, it encounters circulating red blood cells.
   • Free NO binds instantly to the iron in hemoglobin with an affinity approximately 200,000 times greater than that of oxygen ($K_d \approx 10^{-12}\text{ M}$).
   • This reaction rapidly forms nitrosyl-hemoglobin (Hb-NO), which is swiftly oxidized in the presence of oxygen to methemoglobin ($\text{MetHb}$) and inactive nitrate/nitrite compounds.
   • The biological intravascular half-life of free iNO in the blood is $< 0.1\text{ seconds}$ (milliseconds). Consequently, hemoglobin scavenging limits systemic vasodilation and makes the effect predominantly pulmonary. It is not absolute: hypotension is a reported adverse reaction, and increased pulmonary venous return can worsen pulmonary edema in left-ventricular dysfunction.

---

Clinical Indications & Candidacy Criteria

Table 9.1.1: Clinical Indications and Evidence-Based Thresholds for iNO Therapy

The Oxygenation Index (OI)

The Oxygenation Index is an important severity and trajectory measure in invasively ventilated hypoxemic respiratory failure. It supports iNO and ECMO-center decisions but does not independently establish pulmonary hypertension, eligibility, or cannulation:

$\text{Oxygenation Index (OI)} = \frac{\text{Mean Airway Pressure (Paw in }\text{cmH}_2\text{O)} \times \text{FiO}_2 \times 100}{\text{PaO}_2\text{ (in mmHg)}}$

• Lower or rising OI: Optimize lung recruitment and protective ventilation, treat the cause, assess ventricular function and pulmonary pressure, and follow the trajectory.
• iNO consideration: In a term or near-term infant with hypoxic respiratory failure and evidence of pulmonary hypertension after lung recruitment, many protocols consider iNO as OI rises into the mid-teens or higher; eligibility and timing are protocol-specific.
• Severe or sustained elevation: Reassess reversible problems and contact an ECMO-capable center early. An OI around or above 40 is a traditional high-risk trigger for urgent evaluation, not a stand-alone mandate for HFOV or cannulation.

Contraindication & Major Cautions

• Labeled contraindication: Do not use INOmax in a neonate whose survival depends on right-to-left shunting of blood; lowering pulmonary resistance can disrupt the required systemic or pulmonary flow pattern.
• Left-ventricular dysfunction or pulmonary venous obstruction: Increased pulmonary flow can raise wedge pressure and worsen pulmonary edema or heart failure. Review anatomy and ventricular function and stop therapy if this occurs.
• Methemoglobin risk: Baseline red-cell disorders and concurrent oxidant drugs can alter risk. G6PD deficiency is especially relevant if methylene blue is considered for treatment; it is not itself listed as the neonatal INOmax contraindication.

---

Therapeutic Dosing & Dose-Response Mechanics

  Pulmonary Vasodilation & PaO2 Improvement
  ▲
  │                 ┌─────────────────────────────────────────────── (Plateau: Maximal Vasodilation)
  │                / 
  │               /  
  │              /   
  │             /    
  │            /     ◄── Doses > 20 ppm provide NO additional vasodilation,
  │           /          and increase NO2 and methemoglobin exposure
  │          /       
  │         /        
  │        /         
  │       /          
  │      /           
  │     /            
  │    /             
  └────┴─────────────┴──────────────────────────────┴────────────────────────►
  0    5             20                             80                    iNO (ppm)

Clinical Dosing Rules

1. Standard Initial Starting Dose: $20\text{ ppm}$
   • The FDA-labeled recommended neonatal dose is $20\text{ ppm}$. Trials found improved oxygenation and reduced ECMO use in the indicated population; doses above 20 ppm are not recommended because they increase toxic exposure without demonstrated additional benefit.
2. Doses above 20 ppm:
   • Routine escalation above 20 ppm has not shown added outcome benefit in neonatal PPHN and increases nitrogen-dioxide and methemoglobin exposure.
   • If response is inadequate, verify delivery and lung recruitment and reassess cardiac anatomy, ventricular function, disease mechanism, and rescue strategy rather than repeatedly increasing dose.
3. Defining a Clinical "Responder":
   • Define the response before starting: a prompt, reproducible improvement in oxygenation, OI, pulmonary pressure, right-ventricular function, or perfusion at unchanged or reduced support. Exact PaO2 and SpO2 thresholds vary by protocol.
   • If there is no meaningful response after delivery and lung inflation are verified, reassess anatomy, ventricular function, lung disease, and rescue strategy. Routine escalation above 20 ppm has not shown added outcome benefit in neonatal PPHN and increases toxic exposure; any exception requires specialist direction and close NO2 and methemoglobin monitoring.

---